First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis

BACKGROUND: Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICIs in the first-line treatment of patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: wang, Liting, Peng, Ye, Qin, Shuxia, Wan, Xiaomin, Zeng, Xiaohui, Li, Sini, Liu, Qiao, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101629/
https://www.ncbi.nlm.nih.gov/pubmed/37053300
http://dx.doi.org/10.1371/journal.pone.0279786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101629/
https://www.ncbi.nlm.nih.gov/pubmed/37053300
http://dx.doi.org/10.1371/journal.pone.0279786

Ejemplares similares